» Articles » PMID: 35463373

Intrafraction Prostate Motion Management During Dose-Escalated Linac-Based Stereotactic Body Radiation Therapy

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Apr 25
PMID 35463373
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Extreme hypofractionation requires tight planning margins, high dose gradients, and strict adherence to planning criteria in terms of patient positioning and organ motion mitigation. This study reports the first clinical experience worldwide using a novel electromagnetic (EM) tracking device for intrafraction prostate motion management during dose-escalated linac-based stereotactic body radiation therapy (SBRT).

Methods: Thirteen patients with organ-confined prostate cancer underwent dose-escalated SBRT using flattening filter-free (FFF) volumetric modulated arc therapy (VMAT). The EM tracking device consisted of an integrated Foley catheter with a transmitter. Patients were simulated and treated with a filled bladder and an empty rectum. Setup accuracy was achieved by ConeBeam-CT (CBCT) matching, and motion was tracked during all the procedure. Treatment was interrupted when the signals exceeded a 2 mm threshold in any of the three spatial directions and, unless the offset was transient, target position was re-defined by repeating CBCT. Moreover, the displacements that would have occurred without any intrafraction organ motion management (i.e. no interruptions and repositionings) were simulated.

Results: In 31 out of 56 monitored fractions (55%), no intervention was required to correct the target position. In 25 (45%) a correction was mandated, but only in 10 (18%), the beam delivery was interrupted. Total treatment time lasted on average 10.2 minutes, 6.7 minutes for setup, and 3.5 minutes for beam delivery. Without any intrafraction motion management, the overall mean treatment time and the mean delivery time would have been 6.9 minutes and 3.2 minutes, respectively. The prostate would have been found outside the tolerance in 8% of the total session time, in 4% of the time during the setup, and in 14% during the beam-on phase. Predominant motion pattern was posterior and its probability increased with time, with a mean motion ≤ 2 mm occurring within 10 minutes.

Conclusions: EM real-time tracking was successfully implemented for intrafraction motion management during dose-escalated prostate SBRT. Results showed that most of the observed displacements were < 2 mm in any direction; however, there were a non-insignificant number of fractions with motion exceeding the predefined threshold, which would have otherwise gone undetected without intrafraction motion management.

Citing Articles

Dose escalation with stereotactic body radiotherapy for cervical cancer treatment.

Turna M, Rzazade R, Kucukmorkoc E, Kucuk N, Canoglu M, Caglar H BMC Cancer. 2024; 24(1):1281.

PMID: 39407149 PMC: 11481774. DOI: 10.1186/s12885-024-13017-8.


Target Volume Optimization for Localized Prostate Cancer.

Patel K, van der Heide U, Kerkmeijer L, Schoots I, Turkbey B, Citrin D Pract Radiat Oncol. 2024; 14(6):522-540.

PMID: 39019208 PMC: 11531394. DOI: 10.1016/j.prro.2024.06.006.


Pelvic lymph node motion during cone-beam computed tomography guided stereotactic radiotherapy.

Janssen J, Staal F, Langendijk J, Both S, Brouwer C, Aluwini S Clin Transl Radiat Oncol. 2024; 47:100794.

PMID: 38798748 PMC: 11127188. DOI: 10.1016/j.ctro.2024.100794.


Stereotactic body radiation therapy (SBRT) for prostate cancer: Improving treatment delivery efficiency and accuracy.

Mastella E, Epile J, De Guglielmo E, Fabbri S, Calderoni F, Manco L Tech Innov Patient Support Radiat Oncol. 2024; 30:100253.

PMID: 38746647 PMC: 11090872. DOI: 10.1016/j.tipsro.2024.100253.


Electromagnetic Transmitter-Based Prostate Gating for Dose-Escalated Linac-Based Stereotactic Body Radiation Therapy: An Evaluation of Intrafraction Motion.

De Bari B, Guibert G, Slimani S, Bashar Y, Risse T, Guisolan N Curr Oncol. 2024; 31(2):962-974.

PMID: 38392066 PMC: 10887766. DOI: 10.3390/curroncol31020072.


References
1.
Braide K, Lindencrona U, Welinder K, Gotstedt J, Stahl I, Pettersson N . Clinical feasibility and positional stability of an implanted wired transmitter in a novel electromagnetic positioning system for prostate cancer radiotherapy. Radiother Oncol. 2018; 128(2):336-342. DOI: 10.1016/j.radonc.2018.05.031. View

2.
Lee W, Dignam J, Amin M, Bruner D, Low D, Swanson G . Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol. 2016; 34(20):2325-32. PMC: 4981980. DOI: 10.1200/JCO.2016.67.0448. View

3.
Zhu X, Bourland J, Yuan Y, Zhuang T, ODaniel J, Thongphiew D . Tradeoffs of integrating real-time tracking into IGRT for prostate cancer treatment. Phys Med Biol. 2009; 54(17):N393-401. DOI: 10.1088/0031-9155/54/17/N03. View

4.
Masi L, Zani M, Doro R, Calusi S, Di Cataldo V, Bonucci I . CyberKnife MLC-based treatment planning for abdominal and pelvic SBRT: Analysis of multiple dosimetric parameters, overall scoring index and clinical scoring. Phys Med. 2018; 56:25-33. DOI: 10.1016/j.ejmp.2018.11.012. View

5.
Gizynska M, Rossi L, den Toom W, Milder M, de Vries K, Nuyttens J . Largely reduced OAR doses, and planning and delivery times for challenging robotic SBRT cases, obtained with a novel optimizer. J Appl Clin Med Phys. 2021; 22(3):35-47. PMC: 7984474. DOI: 10.1002/acm2.13172. View